A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
Active, not recruiting · Phase 1, Phase 2 · NCT02028455
Conditions: CD19+ Acute Leukemia
At a glance
- Research payments reported, 2025
- $4.3M
- U.S. investigators named
- 14
- Sites paid
- 12
- Planned or actual enrollment
- 167
About the trial
- Sponsor
- Seattle Children's Hospital
- Tested
- Patient Derived CD19 specific CAR T cells also expressing an EGFRt (biological)
- Dates
- Started 2014-02-11; completion 2036-07
- Results posted
- Yes
Patients with relapsed or refractory leukemia often develop resistance to chemotherapy. For this reason, we are attempting to use T cells obtained directly from the patient, which can be genetically modified to express a chimeric antigen receptor (CAR). The CAR enables the T cell to recognize and kill the leukemic cell through the recognition of CD19, a protein expressed of the surface of the leukemic cell in patients with CD19+ leukemia. This is a phase 1/2 study designed to determine the maximum tolerated dose of the CAR+ T cells as well as to determine the efficacy. The phase 1 cohort is restricted to those patients who have already had an allogeneic hematopoietic cell transplant (HCT)…
From ClinicalTrials.gov, last updated 2026-08-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $4.3M in research payments for this study in 2025 (15 payments).
Products named: Breyanzi
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Amitkumar Mehta, MD Hematology & Oncology · Scottsdale, AZ
- Tanya Siddiqi, M.D. Hematology · Duarte, CA
- Michael Wang Radiology · Escondido, CA
- Manali K. Kamdar, MD Hematology & Oncology · Aurora, CO
- Scott R. Solomon, M.D. Specialist · Atlanta, GA
- Leo Gordon, MD Hematology & Oncology · Chicago, IL
- Jeremy S. Abramson, MD Medical Oncology · Boston, MA
- Nilanjan Ghosh, MD Medical Oncology · Charlotte, NC
- Matthew A. Lunning, D.O. Medical Oncology · Omaha, NE
- Jon E. Arnason, MD Internal Medicine · New York, NY
- Maria L. Palomba, MD Hematology & Oncology · New York, NY
- Charalambos I. Andreadis, MD Medical Oncology · Philadelphia, PA
- Alison Sehgal Hematology & Oncology · Pittsburgh, PA
- Luhua M. Wang, M.D. Hematology & Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- City of Hope National Medical Ctr $1.5M
- Memorial Sloan-Kettering Cancer Center - Cancer $665,052
- Ut MD Anderson Cancer Center $429,271
- Northwestern University $365,581
- Unehealth $331,845
- Carolinas Medical Center-Northeast, NC $316,826
- Dana-Farber Cancer Institute $254,391
- Regents of the University of Colorado $161,053
- University of Alabama Hospital, AL $79,370
- University of Pittsburgh $75,083
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $31,516
- Northside Hospital Gwinnett $26,796
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.